![]() |
|
|
Vol. 58, Issue 1, 207-216, July 2000
Department of Pharmacology and Therapeutics, The University of
Liverpool, Liverpool, United Kingdom (D.P.W., M.P., D.J.N., B.K.P.);
and Faculty of Pharmacy, University of Toronto, Ontario, Canada
(J.P.U.)
Clozapine, an atypical antipsychotic used in the treatment of
refractory schizophrenia, causes neutropenia and agranulocytosis in 3 and 0.8% of patients, respectively. Clozapine undergoes bioactivation to a chemically reactive nitrenium ion, which has been shown to cause
neutrophil cytotoxicity. To define further the mechanism of cell death,
we have investigated the toxicity of clozapine, its stable metabolites,
and its chemically reactive nitrenium ion to neutrophils and
lymphocytes. Clozapine was able to induce neutrophil apoptosis at
therapeutic concentrations (1-3 µM) only when it was bioactivated to
the nitrenium ion. The parent drug caused apoptosis at supratherapeutic
concentrations (100-300 µM) only. Neutrophil apoptosis induced by
the nitrenium ion, but not by the parent drug itself, was inhibited by
antioxidants and genistein and was accompanied by cell surface
haptenation (assessed by flow cytometry) and glutathione depletion.
Dual-color flow cytometry showed that neutrophils that were haptenated
were the same cells that underwent apoptosis. No apoptosis of
lymphocytes was evident with the nitrenium ion or the parent drug,
despite the fact that the former caused cell surface haptenation,
glutathione depletion, and loss of membrane integrity.
Demethylclozapine, the major stable metabolite in vivo, showed a
profile that was similar to, although less marked than that observed
with clozapine. N-oxidation of clozapine or replacement
of the nitrogen (at position 5) by sulfur produced compounds that were
entirely nontoxic to neutrophils. In conclusion, the findings of the
study expand on potential mechanisms of clozapine-induced cytotoxicity,
which may be of relevance to the major forms of toxicity encountered in
patients taking this drug.
This article has been cited by other articles:
![]() |
S Vasoo Drug-induced lupus: an update Lupus, November 1, 2006; 15(11): 757 - 761. [Abstract] [PDF] |
||||
![]() |
V. Bhatt and A. Saleem Drug-Induced Neutropenia - Pathophysiology, Clinical Features, and Management Ann. Clin. Lab. Sci., April 1, 2004; 34(2): 131 - 137. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Berliner, M. Horwitz, and T. P. Loughran Jr. Congenital and Acquired Neutropenia Hematology, January 1, 2004; 2004(1): 63 - 79. [Abstract] [Full Text] [PDF] |
||||